Competing risk for CVD mortality and stroke according to AF in patients with HFrEF, HFmrEF and HFpEF
| HFpEF | HFmrEF | HFrEF | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Stroke | ||||||
| Model 1 | 1.900 (1.240 to 2.910) | 0.003 | 1.280 (0.812 to 2.020) | 0.290 | 1.460 (1.040 to 2.050) | 0.027 |
| Model 2 | 1.766 (1.056 to 2.950) | 0.030 | 1.120 (0.659 to 1.904) | 0.680 | 1.544 (1.040 to 2.290) | 0.031 |
| CVD mortality | ||||||
| Model 1 | 1.210 (0.892 to 1.650) | 0.220 | 0.956 (0.658 to 1.390) | 0.810 | 0.882 (0.727 to 1.070) | 0.200 |
| Model 2 | 1.507 (1.005 to 2.260) | 0.047 | 1.049 (0.634 to 1.736) | 0.850 | 0.880 (0.685 to 1.130) | 0.320 |
Model 1: unadjusted.
Model 2: adjusted for sex, age, smoking status, alcohol consumption, medical history (New York Heart Association functional class, hypertension, diabetes mellitus, ischaemic heart disease, renal failure, cancer, prior stroke), heart rate, systolic blood pressure, diastolic blood pressure, body mass index, laboratory examination (white cell count, glycated haemoglobin, potassium, sodium, haemoglobin, blood urea nitrogen, creatinine, BNP or NT-proBNP), and medications before or at admission or at discharge (use of ACE inhibitor or angiotensin receptor blockers, beta-blockers, aldosterone antagonist, nitrate, diuretic, anticoagulant, antiplatelet and statin).
AF, atrial fibrillation; BNP, brain natriuretic peptide; CVD, cardiovascular disease; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.